Ipamorelin, GHRP-2, and GHRP-6 are all synthetic peptides that belong to the same pharmacological family: the growth hormone secretagogues that act as agonists at the ghrelin receptor, formally the growth hormone secretagogue receptor type 1a (GHS-R1a). Because they share a receptor, they are often treated as interchangeable. The published research tells a more interesting story — they differ markedly in selectivity, meaning how cleanly each one acts on the growth-hormone axis versus the extent to which it also moves other pituitary and adrenal hormones in study subjects. This comparison walks through what each compound is at the molecular level and what cited studies actually measured.
The shared mechanism: GHS-R1a agonism
The starting point for all three is the same receptor. A foundational study cloned a G–protein-coupled receptor in the pituitary and hypothalamus and showed it to be the molecular target of the synthetic growth hormone secretagogues, including GHRP-6 (Howard et al., Science, 1996). That receptor — GHS-R1a — was later shown to be the receptor for the stomach hormone ghrelin, which is why these compounds are described as ghrelin mimetics: they activate the same receptor ghrelin does, despite sharing no sequence similarity with it.
What separates the members of the family is not the receptor they bind but the breadth of the hormonal response that binding produces. GHS-R1a is expressed in tissues beyond the GH-releasing cells of the pituitary, and the less selective members engage that broader distribution. The selectivity question is therefore the central one when these compounds are compared:
- Does the compound stimulate growth hormone (GH) more or less in isolation?
- Or does it also raise cortisol and ACTH (the adrenal axis) and prolactin?
- Does it activate the appetite-regulating circuitry that ghrelin itself drives?
Ipamorelin: the selective end of the family
Ipamorelin is a synthetic pentapeptide — five amino acids — and it is the compound that defined the selective end of this class. The landmark characterization study described it as “the first selective growth hormone secretagogue” and tested its specificity directly (Raun et al., European Journal of Endocrinology, 1998). In that work, ipamorelin released GH in the research models studied, but, very notably, it did not raise ACTH or cortisol to levels significantly different from those seen with GHRH alone, and it showed no significant effect on prolactin — a separation that the authors reported remained intact across a wide range of exposures, far beyond the level needed to release GH.
That measured profile — GH-axis activity without a parallel rise in the adrenal-axis and prolactin hormones — is what “selective” means here, and it is the property that distinguishes ipamorelin from the older hexapeptides below. The comparison is purely about the hormonal fingerprint observed in research subjects; it is not a statement about any outcome in any individual.
GHRP-2 and GHRP-6: potent, but less selective
GHRP-2 (also known as pralmorelin) and GHRP-6 are both synthetic hexapeptides — six amino acids — and both are potent GH secretagogues at GHS-R1a. Where they diverge from ipamorelin is in the off-target hormonal activity that accompanies the GH response. A human comparison study measured GHRP-2 alongside hexarelin against GHRH, TRH, and human CRH, and reported that both peptides produced potent GH release while also raising ACTH and cortisol to a degree comparable to CRH, along with a measurable prolactin response (Arvat et al., Peptides, 1997). In other words, the published data placed GHRP-2 firmly in the less-selective group: strong on GH, but not isolated to it.
GHRP-6 was the earliest clinically studied member of the family and carries an additional dimension that distinguishes it within the group: a pronounced link to appetite circuitry. Because GHS-R1a is the ghrelin receptor, and ghrelin is an appetite-stimulating signal, the secretagogues can in principle engage feeding pathways — and GHRP-6 is the member where this was most clearly demonstrated. A study in rats found that central administration of GHRP-6 significantly stimulated food intake and activated brain appetite centers, including the hypothalamus and orexin-producing neurons (Lawrence et al., Endocrinology, 2002). That finding describes what the compound did in a research model; it is reported here as a selectivity characteristic, not as a benefit.
Where Hexarelin fits, and how to read the spectrum
Hexarelin (also called examorelin) is another synthetic hexapeptide in the same family, derived structurally from GHRP-6, and it is one of the most potent GH secretagogues of the group. In the same human comparison that examined GHRP-2, hexarelin was measured side by side and showed a similar pattern: potent GH release accompanied by ACTH, cortisol, and prolactin activity (Arvat et al., Peptides, 1997). It therefore sits with GHRP-2 and GHRP-6 on the potent-but-broad side of the spectrum rather than the selective side.
Laid out together, the family forms a clear gradient defined by selectivity rather than by raw GH potency:
- Ipamorelin — pentapeptide; reported in study models to stimulate GH with minimal measured effect on cortisol, ACTH, and prolactin.
- GHRP-2 — hexapeptide; potent GH secretagogue that also raised ACTH, cortisol, and prolactin in the cited human study.
- GHRP-6 — hexapeptide; potent GH secretagogue additionally associated with appetite-center activation in a research model.
- Hexarelin — hexapeptide; among the most potent of the group, with a measured off-target hormonal profile resembling GHRP-2’s.
Read across that list, the variable that separates these compounds is consistent: every one is a GHS-R1a agonist, but ipamorelin’s published profile shows the cleanest separation between GH-axis activity and the cortisol, prolactin, and appetite responses the hexapeptides carry.
Frequently asked questions
Are ipamorelin, GHRP-2, and GHRP-6 the same type of compound?
Yes, in the broad sense: all three are synthetic peptides that act as agonists at the ghrelin receptor, GHS-R1a, and are classed as growth hormone secretagogues. They differ in length — ipamorelin is a pentapeptide, GHRP-2 and GHRP-6 are hexapeptides — and, more importantly, in their measured selectivity.
What makes ipamorelin “selective” compared with GHRP-2 and GHRP-6?
In its characterization study, ipamorelin stimulated GH in the research models tested but did not significantly raise ACTH, cortisol, or prolactin relative to GHRH alone (Raun et al., 1998). GHRP-2 and GHRP-6, by contrast, were reported to raise the adrenal-axis hormones and prolactin alongside GH, which is what places them in the less-selective group.
What is the main difference between GHRP-2 and GHRP-6?
Both are potent hexapeptide secretagogues at the same receptor. In the published literature, GHRP-2 is generally described as the more potent GH releaser, while GHRP-6 is the member most clearly associated with appetite-center activation — central GHRP-6 stimulated food intake in a rat model (Lawrence et al., 2002).
Why are these called ghrelin mimetics?
GHS-R1a, the receptor all of these peptides bind, is the same receptor activated by the natural hormone ghrelin (Howard et al., 1996). The synthetic peptides reproduce ghrelin’s receptor activation despite having no sequence resemblance to ghrelin, which is why they are described as ghrelin mimetics.
Where does hexarelin sit relative to the others?
Hexarelin is a hexapeptide derived from GHRP-6 and is one of the most potent members of the family. In the same human study that measured GHRP-2, hexarelin showed a comparable off-target profile, with ACTH, cortisol, and prolactin activity accompanying GH release (Arvat et al., 1997), placing it on the potent-but-less-selective side of the spectrum.
Do all four bind the same receptor?
Yes. Ipamorelin, GHRP-2, GHRP-6, and hexarelin are all agonists at GHS-R1a, the growth hormone secretagogue receptor. The differences between them lie in the breadth of the hormonal response that receptor activation produced in the cited studies, not in the identity of the receptor itself.
References
- Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996. PMID: 8688086.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822.
- Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997. PMID: 9285939.
- Lawrence CB, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002. PMID: 11751604.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
